Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 2 de 2
Filter
Add more filters











Database
Language
Publication year range
1.
Hormones (Athens) ; 21(2): 229-240, 2022 Jun.
Article in English | MEDLINE | ID: mdl-35212917

ABSTRACT

PURPOSE: This study aimed to evaluate the antioxidant and antidiabetic properties of clove essential oil (CEO) and to elucidate its mode of action, using selected biochemical targets, relevant to diabetes, and, specifically, its inhibitory effect on the polyol pathway. METHODS: In the current study, CEO was examined for its inhibitory effects on aldose reductase in silico, in vitro, and in vivo, as well as its antioxidative activity. RESULTS: In silico docking studies showed that all the selected major compounds of CEO have an energy change ranging between - 5.5 and - 8.8 kcal/mol and an inhibition constant ranging between 357.08 nM and 93.12 µM. CEO significantly inhibits aldose reductase with an IC50 value of 58.55 ± 5.84 µg/mL in a noncompetitive manner. The supplementation of CEO at 20 mg/kg BW decreases retinal sorbitol dehydrogenase activity via decreased aldose reductase activity in streptozotocin (STZ)-induced diabetic Sprague Dawley rats. Moreover, diabetic rats injected with CEO have exhibited improved levels of glycemia. The IC50 values for ABTS, hydroxyl, and hydrogen peroxide scavenging activities of CEO were found to be 34.42, 277.4, and 39.99 µg/mL, respectively. Reducing power assay and phosphomolybdate assay exhibited a reduction force with the A0.5 values of 50.25 and 140.16 µg/mL, respectively. CONCLUSION: CEO potentially exerts a beneficial effect on diabetes-related complications due to its antioxidant and inhibitory effect on aldose reductase activity.


Subject(s)
Aldehyde Reductase/antagonists & inhibitors , Diabetes Mellitus, Experimental , Oils, Volatile , Syzygium , Aldehyde Reductase/metabolism , Animals , Antioxidants/pharmacology , Diabetes Mellitus, Experimental/complications , Diabetes Mellitus, Experimental/drug therapy , Diabetes Mellitus, Experimental/metabolism , Enzyme Inhibitors/adverse effects , Enzyme Inhibitors/chemistry , Humans , Oils, Volatile/adverse effects , Rats , Rats, Sprague-Dawley , Syzygium/metabolism
2.
Article in English | MEDLINE | ID: mdl-32991999

ABSTRACT

The main purpose of the present study was to investigate the ability of ethyl acetate fraction (EAF) from Ephedra fragilis to function as a protective agent against hydrogen peroxide induced oxidative damage in Tetrahymena pyriformis. The cells were preincubated with EAF (50-200 µg/mL) or ascorbic acid (50 µg/mL) for 24 h, followed by incubation with 50% H2O2 inhibitory concentration for 48 h. Cell viability was assessed using trypan exclusion method. Cell morphology and mobility, antioxidant enzymes activities (catalase (CAT), superoxide dismutase (SOD) and glutathione reductase (GR)), malondialdehyde (MDA) and protein carbonyl (PCO) levels, DNA fragmentation and metabolic enzymes activities (succinate dehydrogenase (SDH) and NADPH-cytochrome c reductase (NCCR)) were investigated. Our results indicate that, pretreatment of T. pyriformis cells with EAF improved the cell viability, restored normal cell mobility and morphology, decreased the levels of both MDA and PCO level, prevent DNA fragmentation and enhanced the activity of antioxidant (CAT, SOD and GR) and metabolic (SDH and NCCR) enzymes in H2O2 damaged cells. In conclusion, these results suggest for the first time that E. fragilis is a promising source of natural antioxidants, that could offer protection against oxidative stress and should be further exploited for its use in clinical medicine.


Subject(s)
Antioxidants/pharmacology , Ephedra/chemistry , Oxidative Stress/drug effects , Plant Extracts/pharmacology , Tetrahymena pyriformis/drug effects , Biomarkers/metabolism , Cell Movement/drug effects , Cell Survival/drug effects , Hydrogen Peroxide/toxicity , Protozoan Proteins/metabolism
SELECTION OF CITATIONS
SEARCH DETAIL